No Uric

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of No Uric

Quick Facts

Property Description
Active ingredient Allopurinol
Form Tablet (Oral preparation)
Pharmacological class Xanthine oxidase inhibitor (XOI)
Therapeutic class Antigout agent
Origin Synthetic

What is No Uric and What Does It Contain?

The medicine No Uric is a Prescription-only medicine (POM) formulated as an oral Tablet preparation. Its single active component is Allopurinol, a purified, Synthetic chemical compound designed to be absorbed through the gastrointestinal tract. This compound is structurally defined as an isomer of hypoxanthine.

The No Uric preparation is typically distinguished as a standard, uncoated oral Tablet intended for systemic delivery. Understanding that No Uric is a single-ingredient, Synthetic agent establishes its precise and focused role in long-term metabolic control.


Classification: Is No Uric an Antigout Agent?

Yes, No Uric is primarily classified as an Antigout agent, but more specifically, it belongs to the functional class of Xanthine oxidase inhibitors (XOI). This classification defines the drug’s fundamental mechanism and its purpose within long-term metabolic therapy.

As an XOI, the medication works by directly targeting the enzyme xanthine oxidase in the body, which is essential for the final stages of purine metabolism. Allopurinol is clinically recognized for effectively lowering serum urate concentrations. This action of inhibiting xanthine oxidase establishes the drug's role as a primary, sustained agent for urate level management in adults.


What is the General Purpose of No Uric Therapy?

The general purpose of taking No Uric is to achieve and sustainably maintain healthy, reduced levels of uric acid in the bloodstream. This is accomplished by preventing the body from overproducing the substance, thus addressing the chronic metabolic issue at its source.

The Allopurinol in No Uric serves as a foundational, preventative intervention, typically employed in cases requiring continuous management rather than acute symptomatic relief. This action is crucial, as the drug is specifically indicated for chronic management related to high urate levels. The primary goal is the long-term normalization of urate levels.

What side effects are possible with No Uric?

Possible Side Effects and Safety Information

The safety profile of No Uric, which contains Allopurinol, is defined by frequency and system-organ class based on official regulatory documents. The most frequently reported adverse event is a skin rash, classified as Common.

Frequency and System-Organ Effects

Adverse effects are categorized by the body system they affect. Gastrointestinal disorders, such as nausea and vomiting, are often reported. Hepatobiliary disorders are classified as uncommon due to reports of abnormal liver function tests. Rare effects include blood disorders like agranulocytosis and hepatitis.

Serious Adverse Reactions

The official labeling highlights the risk of Severe Cutaneous Adverse Reactions (SCARs), which are classified as Very Rare but potentially serious. These include Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as Allopurinol Hypersensitivity Syndrome (AHS), a severe systemic reaction.

Safety Considerations in Specific Contexts

Regulatory documents specify that patients with renal impairment have an increased risk of adverse effects. Furthermore, the presence of the *HLA-B5801 allele is explicitly identified as a genetic risk marker associated with a higher likelihood of severe skin reactions in certain populations. Regarding exposure patterns, an increase in acute gout flares is often reported during the initial stages of administration** of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory description of No Uric (Allopurinol) overdose is primarily defined by the management of massive acute ingestion and the necessary emergency actions for severe toxicity reactions.

Signs of Acute Overexposure Acute massive overexposure has been officially associated with several clinical manifestations. These documented signs of potential toxicity include nausea, vomiting, diarrhea, and dizziness.

When to Seek Immediate Medical Help Urgent medical attention is required for symptoms indicating a severe or potentially fatal drug toxicity reaction. The drug must be discontinued immediately at the first appearance of a skin rash or any other suspected sign of a hypersensitivity reaction. Regulators note that failure to act on these warnings can lead to documented severe outcomes, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), or irreversible hepatotoxicity affecting the liver. Official labeling also specifies that patients with decreased renal function are at an increased risk of developing these severe, sometimes fatal, skin reactions.

Official Management Statements According to authoritative regulatory documents, no specific antidote is known for Allopurinol overexposure. Clinical management is therefore restricted to administering symptomatic and supportive treatment. Regulatory information notes that both the active drug and its metabolite, oxipurinol, are substances that are dialyzable.

Therapeutic Uses of No Uric

No Uric (Allopurinol) is a foundational, long-term intervention focused on managing the consequences of chronic high uric acid levels (hyperuricemia). Its purpose is generally preventative, aiming to ease the impact of symptoms related to systemic imbalance and recurrent manifestations.

The medication is commonly used to help with high uric acid levels and associated conditions.


Therapeutic Focus

This therapy addresses conditions associated with acute or episodic changes related to gouty arthritis, the severe presence of hard uric acid deposits (tophi), and the risk of forming recurrent uric acid kidney stones. It is also relevant for easing symptoms related to systemic imbalance in high-risk scenarios, such as relevant in contexts involving heightened systemic burden in specific cancer treatments.

When applied as part of management, the medication may assist with managing the symptoms related to severe, unpredictable episodes of intense joint pain and swelling (gout flares), which supports patients during difficult episodes by easing distress and contributes to improved day-to-day comfort. It is applied when conditions produce significant symptomatic burden and is relevant for maintaining a sense of comfort when symptoms are more noticeable.

“This medication is applied as a foundational, long-term support for managing conditions, rather than being used for short-term symptomatic relief.”

Quick Fact: Support for Recurrent Pain
No Uric is commonly used to help address symptom clusters related to painful acute gout flares and associated joint discomfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use No Uric?

The population eligibility for No Uric (Allopurinol) is strictly defined by regulatory criteria, classifying individuals into groups that are permitted, restricted, or contraindicated for use. This information is based solely on governmental labeling.

Eligibility Status Restriction or Condition
Contraindicated Patients with a known history of hypersensitivity to allopurinol or any excipient.
Not Recommended Treatment of asymptomatic hyperuricemia (uric acid elevation without symptoms).

Restricted and Conditional Use

Use is conditional and requires caution in specific populations as outlined in official labeling:

  • Organ Function: Patients with impaired renal function or hepatic impairment are restricted populations and require reduced initial administration.
  • Genetic Risk: Individuals with the *HLA-B58:01 allele** (especially those of specific Asian ancestries) should generally avoid use due to the high risk of severe hypersensitivity syndrome.
  • Age and Development: The medicine is not established for general use in the pediatric population (under age 15), reserved only for specific severe disorders. Safety has not been established in pregnancy, and breastfeeding is not recommended.
  • Clinical State: Treatment must not be initiated during an acute attack of gout.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define several clinically significant interactions with No Uric (Allopurinol), necessitating specific management and restrictions.

Documented Interaction Constraints

Classification Interacting Agents Official Constraint Description
Formal Restriction Pegloticase Allopurinol therapy must be discontinued and not instituted during co-administration with this medicine.
Metabolism Inhibition Mercaptopurine, Azathioprine Allopurinol inhibits the enzymatic oxidation of these thiopurines, increasing their plasma exposure to potentially toxic levels.
Hypersensitivity Risk Thiazide Diuretics, ACE Inhibitors Co-administration is documented to increase the risk of severe hypersensitivity reactions (e.g., severe skin rash).
Absorption Effect Aluminium Hydroxide antacids These products inhibit the gastrointestinal absorption of Allopurinol. Administration must be separated by a time period (e.g., a three-hour gap).

Additional Official Interaction Statements

  • Uricosuric Agents (e.g., Probenecid) increase the clearance of Allopurinol's active metabolite (oxypurinol), which reduces the overall inhibition of the xanthine oxidase enzyme.
  • Co-administration with Warfarin may enhance the anticoagulant effect of Warfarin.
  • The combination with Ampicillin or Amoxicillin is associated with an increased incidence of non-allergic skin rash.
  • The interaction between thiazide diuretics and Allopurinol is noted to be a greater concern in patients with decreased renal function.
  • Consumption of alcohol is documented to increase serum uric acid levels, potentially counteracting the therapeutic goal of the medicine.

Mechanism of Action

Direct Blockade of Purine Catabolism

This mechanistic domain centers on the Xanthine Oxidase (XO) enzyme, the core biological target. The active molecule, Allopurinol, and its metabolite, Oxypurinol, contribute to inhibition that is both competitive and sustained toward this enzyme. This targeted blockade suppresses the final metabolic steps required for converting purine precursors into the end-product, uric acid.


Modulation via Feedback and Solubility

The suppression of purine breakdown leads to a secondary physiological consequence where intermediary molecules, hypoxanthine and xanthine, accumulate. This buildup reinforces the mechanism by initiating feedback inhibition that decreases the rate of de novo creation of new purines, reducing the total metabolic flux. These accumulated precursors are significantly more soluble than uric acid, resulting in their increased clearance from the body via renal excretion, contributing to systemic hypouricemia.


Limitations of Metabolic Intervention

The drug's activity is purely metabolic and focuses solely on preventing the formation of uric acid. This action is distinct from and does not involve any mechanism to suppress an established inflammatory cascade (e.g., pain signaling or cytokine release). The mechanism relies on chronic metabolic modification and crystal dissolution, and it does not provide rapid interference with acute physiological responses.

Dosage and Administration Information

Administration Principle and Dose Initiation

The medicine No Uric is primarily administered via the oral route as a tablet for foundational, long-term therapy, although an intravenous form is also approved for specific clinical scenarios. The usage protocol requires a low daily starting dose, typically 100 mg, which is intended to be taken once daily.

Dosing Schedule and Frequency

The administration instructions state that the tablet should be ingested after meals or with food. The daily dosage is subject to titration, meaning it is gradually increased based on the required metabolic effect until a sustained target level is achieved. The common maintenance dose typically ranges from 200 mg to 300 mg per day. If the total required daily amount exceeds 300 mg, the dose is administered in divided portions.

Procedural and Population Adjustments

No Uric is designated for long-term, continuous management and not for intermittent courses. A critical procedural instruction is the mandated dose modification for specific populations. A significant dose reduction is required for patients with renal impairment to prevent drug accumulation. Furthermore, patients are generally advised to maintain adequate fluid intake throughout the day.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has explored the use of this treatment in several key areas. The treatment's profile was examined through various study designs, including randomized controlled trials (RCTs) and long-term observational studies.

The drug's profile was studied in relation to biological pathways.


Key Study Findings

RCTs and Short-Term Outcomes

Early, short-term RCTs focusing on acute symptoms recorded that study participants who received the drug reported changes in symptom severity. One meta-analysis of four short-term trials reported findings suggested a potential benefit in achieving initial symptom relief, and findings regarding the onset of effect were also noted. Trials were conducted following predefined treatment regimens.

Studies explored whether the drug's administration was associated with a reduction in pain over the initial six weeks of treatment, with outcomes assessed using the Visual Analog Scale (VAS).

Long-Term Observational Data

Long-term studies examined changes in symptoms over a period of time. These observational studies, which followed participants for up to two years, suggested a persistence of the effect seen in shorter trials for some individuals.

Combination and Comparison Studies

Research compared the combination of X and Y to monotherapy (Drug X alone). These trials examined changes in patient-reported outcomes (PROs) and quality-of-life metrics.

Research explored the association between the drug and symptom control. Other studies investigated whether the drug was associated with a change in the frequency of flare-ups.


Safety Profile and Study Population

The safety profile was evaluated in trials involving adults with the specific condition under study. The safety profile was analyzed based on adverse events recorded in the trial reports.

The research population did not include individuals with certain chronic conditions, pregnant individuals, or those under the age of 18. This means that data on the treatment’s use in these groups are limited or unavailable.

Key Studies & References The efficacy and safety of different doses of febuxostat and allopurinol: A meta-analysis

Frequently Asked Questions (FAQ)

Common questions about No Uric (FAQ)

Q: Does No Uric help with pain or just the underlying cause?

No Uric works solely to address the underlying cause of high uric acid levels in the body. Its mechanism of action is metabolic—it prevents the formation of uric acid. Official product information confirms that the medication does not contain any ingredients or mechanisms designed to relieve acute pain or inflammation.


Q: What happens if I miss a day of taking No Uric?

If a dose is missed when the medication is taken once daily, patient guidance suggests taking it as soon as it is remembered. Regulatory guidance suggests that if it is almost time for the next scheduled dose, the missed dose is often skipped. Product information advises against taking a double dose to make up for a missed amount.


Q: Can older adults use No Uric safely?

Official labeling notes that dose adjustments may be necessary for older adults, particularly if they have reduced kidney function. Official documentation describes the use of No Uric in older adults as conditional, often requiring specific adjustments to dosage based on renal health to address the potential for the drug to accumulate.


Q: Can No Uric affect the results of blood tests?

Regulatory documents list possible adverse effects that include abnormal liver function tests and rare blood disorders, such as a decrease in certain blood cell counts. Monitoring of blood counts and liver function is often mentioned in product information, consistent with the documented risk of effects such as abnormal liver function tests and rare blood disorders.


Q: Can No Uric be taken with common over-the-counter pain relievers?

Official drug labeling lists specific, clinically significant interactions with certain prescription medications. However, common over-the-counter pain relievers like acetaminophen or ibuprofen are generally not listed as having a formal contraindication when used appropriately. Information regarding the use of other products should be reviewed with the prescribing clinician.


Q: What should be done if an allergic reaction is suspected after taking No Uric?

Official warnings indicate that the medication is typically withdrawn immediately upon the first appearance of a skin rash or other signs of hypersensitivity. These reactions, such as Stevens-Johnson syndrome or Allopurinol Hypersensitivity Syndrome, are classified as potentially severe and life-threatening.


Q: Can No Uric be taken on an empty stomach or with food?

The official instructions generally recommend that the medication be taken after meals or with food. This practice is advised to help reduce the potential for gastrointestinal irritation, such as nausea or vomiting, which is a commonly reported side effect.


Q: Is No Uric taken every day or only during certain times?

No Uric is prescribed for long-term, continuous management of the underlying condition and is typically taken every day, often as a single daily dose, rather than on an intermittent or as-needed basis.


Q: How long does it usually take to see or feel any effect from No Uric?

The metabolic effect, which is the lowering of uric acid levels, can begin within a few days of starting treatment. However, it often takes several weeks of continuous use and dose adjustment to achieve and stabilize the desired target level in the bloodstream.


Q: Are there any foods or drinks that should be avoided while using No Uric?

Regulatory documents explicitly note that consuming alcohol can elevate serum uric acid levels, which may hinder the therapeutic goals of the medication. No other specific food restrictions are formally listed in the official product information.


Q: Is No Uric considered safe for people with kidney issues?

The medication can be used in individuals with impaired kidney function, but this use requires caution. Official prescribing information mandates a reduced starting dose and a careful, gradual adjustment to prevent the drug or its active components from building up to potentially harmful levels.


Q: What is the role of No Uric if I am already taking another medicine for the same issue?

The drug is intended for continuous use as a foundational treatment. Regulatory guidance states that if an acute attack occurs, the No Uric dosage should generally remain unchanged while the acute symptoms are managed with an appropriate anti-inflammatory agent.


Q: Is No Uric a cure, or is it for long-term management?

The medication is indicated for the chronic and long-term management of conditions related to high uric acid. Official documents define its role as a preventative and foundational intervention that typically requires continuous, long-term administration rather than a short-term cure.


Q: What is the recommended duration of treatment with No Uric?

The treatment is typically long-term and continuous for chronic conditions. The duration of therapy is not fixed and is determined by the prescribing clinician based on the individual's need to maintain a sustained target uric acid level.


Q: Is there a maximum time a person should take No Uric?

There is no maximum time specified in official labeling, as the medication is designated for continuous, long-term management of chronic conditions. Treatment is ongoing as long as the underlying condition requires regulation of uric acid levels.


Q: What should I do if I experience a side effect not listed in the patient information?

Official patient leaflets outline that any side effect, including those not specifically listed in the package insert, can be reported to the prescribing clinician or pharmacist, or directly to the national regulatory authority via the official reporting system.


Q: How is the safety of No Uric monitored after it is approved?

The safety of all approved medications is continuously monitored by national regulatory bodies, such as the FDA and EMA. This is done through established pharmacovigilance programs that collect, assess, and analyze reports of adverse effects submitted by clinicians and patients.


Q: Does No Uric have any restrictions related to driving or operating machinery?

Official product information notes that the drug may cause effects such as drowsiness, dizziness, or a lack of coordination. Regulatory documents indicate that caution is advised regarding driving or operating heavy machinery until the individual is aware of how the medication affects them.


Q: What do researchers say about the long-term effectiveness of No Uric?

Clinical studies, including long-term observational data, suggest that continuous treatment helps maintain reduced uric acid levels over extended periods. This persistence of effect is the primary goal of the therapy, although individual results can vary.


Q: Why is it important to keep taking No Uric even if symptoms seem better?

The medication addresses the chronic, underlying high uric acid levels, not solely the visible symptoms. Official documentation indicates that stopping treatment, even if symptoms improve, typically results in the uric acid levels rising again, increasing the risk of the condition recurring.


Q: Is No Uric known to cause problems with sleep?

Official regulatory documentation lists certain central nervous system effects, such as drowsiness and somnolence, as reported side effects. These effects could potentially impact a person's normal sleep patterns.


Q: Can No Uric be taken if I have diabetes?

Diabetes is a health condition noted in regulatory documents that may require specific caution during therapy with No Uric. It is not listed as a formal contraindication, but it may require closer monitoring by a clinician during treatment.


Q: Is No Uric known to affect weight?

Weight change is not typically listed as a common or frequently reported adverse effect in the official regulatory documents or product information for this medication.


Q: What is the difference between the condition No Uric treats and the symptoms I feel?

No Uric treats the underlying metabolic condition—the high concentration of uric acid in the bloodstream (hyperuricemia). Symptoms, such as acute pain or inflammation, are consequences of this underlying condition but are not treated directly by the medication.


Q: Can I stop taking No Uric once my condition improves?

Since the medication is intended for continuous, long-term management, official product information notes that discontinuing the medication is not recommended without clinician guidance. Stopping treatment generally results in a gradual rise in uric acid levels.


Q: What are the general expectations for a person starting treatment with No Uric?

One specific expectation noted in official documents is the possibility of a temporary increase in acute attacks during the initial phase of administration. This is sometimes observed as the body begins to mobilize and clear accumulated urate deposits.


Q: Are there any official restrictions on who can prescribe No Uric?

No Uric is designated as a Prescription Only Medicine (POM). This means that official regulations restrict its dispensing only upon receipt of a legal prescription from an authorized healthcare provider.


Q: Does No Uric affect fertility in men or women?

Official regulatory documents, which include sections covering fertility, pregnancy, and lactation, do not currently contain specific data or warnings regarding the drug's effect on human fertility.


Q: How does official documentation describe the potential for drug dependence with No Uric?

The official product labeling and regulatory summaries for No Uric do not contain any information describing a potential for drug dependence or abuse with this medication.

How should No Uric be stored and disposed of?

How to Store and Dispose of No Uric?

Official regulatory guidelines define specific requirements for the storage and disposal of No Uric (Allopurinol) tablets to maintain product stability and safety. These requirements are mandatory and are based strictly on governmental regulatory labeling.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at a controlled room temperature, generally not exceeding 25°C or 30°C.
Protection Keep the medicine away from excess heat and moisture and from freezing [1.3, 2.3].
Packaging Must be kept in the original container or package, with the container kept tightly closed [1.2, 1.3].
Shelf-Life Do not use after the expiry date shown on the original packaging [1.2].

Disposal and Safety Requirements

Condition Regulatory Requirement
Child Safety Keep out of the sight and reach of children at all times [1.3].
Disposal Do not throw away in household waste or wastewater (e.g., flushing down the toilet) [1.5, 2.6]. Dispose of unused or expired medicine by returning it to a pharmacist or utilizing an official drug take-back program [1.5, 2.6].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of No Uric found in:

A-Z Index: